Idasanutlin - CAS 1229705-06-9
Catalog number:
Not Intended for Therapeutic Use. For research use only.
MDM-2, p53
Idasanutlin; also known as RG7388 and RO5503781, is a highly potent and selective MDM2 antagonist with potential anticancer activity. RG7388 binds to MDM2 blocking the interaction between the MDM2 protein and the transcriptional activation domain of the tumor suppressor protein p53. By preventing the MDM2-p53 interaction, p53 is not enzymatically degraded and the transcriptional activity of p53 is restored. This may lead to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger nuclear phosphoprotein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.
Publictions citing BOC Sciences Products
  • >> More
Solid powder
RG7388; RG 7388; RG-7388; RO5503781; RO-5503781; RO 5503781
For research used only
Current Developer:
1.Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2 selective antagonist idasanutlin (RG7388).
Herting F1, Herter S2, Friess T1, Muth G1, Bacac M2, Sulcova J2, Umana P2, Dangl M1, Klein C2. Eur J Haematol. 2016 Mar 19. doi: 10.1111/ejh.12756. [Epub ahead of print]
OBJECTIVES: To investigate whether the glycoengineered, type II anti-CD20 monoclonal antibody obinutuzumab (GA101) combined with the selective MDM2 antagonist idasanutlin (RG7388) offers superior efficacy to monotherapy in treating B-lymphoid malignancies in preclinical models METHODS: The combined effect of obinutuzumab or rituximab plus idasanutlin on direct cell death/apoptosis induction and antibody-dependent cellular cytotoxicity (ADCC) was evaluated using p53 wild-type Z-138 and DoHH-2 lymphoma cells. Furthermore, whole blood B-cell depletion was analysed, and tumour growth inhibition was evaluated in subcutaneous xenograft models RESULTS: Idasanutlin induced concentration-dependent death of Z-138 and DoHH-2 cells. At concentrations >10-100 nM, idasanutlin enhanced obinutuzumab-induced death of DoHH-2 and Z-138 cells without negatively impacting obinutuzumab-mediated ADCC, natural killer cell activation, or whole blood B-cell depletion.
2.Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans.
Glenn KJ1,2, Yu LJ1, Reddy MB1,3, Fretland AJ1,4, Parrott N5, Hussain S1,6, Palacios M1,7, Vazvaei F1, Zhi J8, Tuerck D5. Xenobiotica. 2016 Aug;46(8):667-76. doi: 10.3109/00498254.2015.1110761. Epub 2015 Nov 19.
1. Idasanutlin (RG7388) is a potent p53-MDM2 antagonist currently in clinical development for treatment of cancer. The purpose of the present studies was to investigate the cause of marked decrease in plasma exposure after repeated oral administration of RG7388 in monkeys and whether the autoinduction observed in monkeys is relevant to humans. 2. In monkey liver and intestinal microsomes collected after repeated oral administration of RG7388 to monkeys, significantly increased activities of homologue CYP3A8 were observed (ex vivo). Investigation using a physiologically based pharmacokinetic (PBPK) model suggested that the loss of exposure was primarily due to induction of metabolism in the gut of monkeys. 3. Studies in monkey and human primary hepatocytes showed that CYP3A induction by RG7388 only occurred in monkey hepatocytes but not in human hepatocytes, which suggests the observed CYP3A induction is monkey specific. 4. The human PK data obtained from the first cohorts confirmed the lack of relevant induction as predicted by the human hepatocytes and the PBPK modelling based on no induction in humans.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related MDM-2, p53 Products

CAS 881202-45-5 Serdemetan

(CAS: 881202-45-5)

Serdemetan, also known as JNJ-26854165, is an orally bioavailable, small-molecule HDM2 antagonist with potential antineoplastic activity. HDM2 antagonist JNJ-2...

CAS 213261-59-7 RITA (NSC 652287)

RITA (NSC 652287)
(CAS: 213261-59-7)

CAS 1313367-56-4 NVP-CGM097 sulfate

NVP-CGM097 sulfate
(CAS: 1313367-56-4)

NVP-CGM097 sulfate, a dihydroisoquinolinone derivative, is a potent and selective MDM2 inhibitor (IC50= 1.7±0.1 nM for hMDM2) in the treatment of p53wt tumors.

CAS 60477-34-1 Pifithrin-β

(CAS: 60477-34-1)

Pifithrin-β is a potent p53 inhibitor (IC50=23 uM) in an antiproliferative, showing a conformation similar to those of the prototypical AhR ligand β-naphthoflav...

CAS 1313363-54-0 CGM097

(CAS: 1313363-54-0)

CGM097 is an orally bioavailable HDM2 (human homolog of double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, p53/HDM2 i...

(CAS: 803647-40-7)

NSC59984 is a p53 pathway activator via induction of mutant p53 protein degradation and p73 activation.

CAS 1303607-60-4 MI-773

(CAS: 1303607-60-4)

MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

CAS 63208-82-2 Pifithrin-α

(CAS: 63208-82-2)

Pifithrin-α is an inhibitor of p53, inhibiting p53-dependent transactivation of p53-responsive genes.

CAS 675576-98-4 Nutlin-3a

(CAS: 675576-98-4)

Nutlin-3a is an inhibitor of MDM2 (human homolog of murine double minute 2), which disrupts its interaction with p53, leading to the stabilization and activatio...

CAS 1364488-67-4 YH239-EE

(CAS: 1364488-67-4)

YH239-EE inhibits the growth of OCI-AML-3 cells with wild type p53 by inhibiting the p53-MDM2 interaction.

(CAS: 1303607-07-9)

MI-773, a spirooxindole derivative, is a MDM2 antagonist that has probable effect in the treatment of sorts of cancers. It has already discontinued the Phase I ...

CAS 548472-68-0 Nutlin-3

(CAS: 548472-68-0)

Nutlin-3 is MDM2 antagonist, inhibits p53-Mdm2 interaction (IC50=0.09 µM).

CAS 939981-39-2 RO5045337

(CAS: 939981-39-2)

RO5045337, also known as R7112, RG7112, is a MDM2 antagonist with potential antineoplastic activity. RO5045337 binds to MDM2, thereby preventing the binding of...

CAS 71555-25-4 NSC 319726

NSC 319726
(CAS: 71555-25-4)

NSC319726 is a p53(R175) mutant reactivator, exhibits growth inhibition in cells expressing mutant p53, with IC50 of 8 nM for p53(R175) mutant, shows no inhibit...

CAS 1229705-06-9 Idasanutlin

(CAS: 1229705-06-9)

Idasanutlin; also known as RG7388 and RO5503781, is a highly potent and selective MDM2 antagonist with potential anticancer activity. RG7388 binds to MDM2 block...

CAS 431979-47-4 SJ 172550

SJ 172550
(CAS: 431979-47-4)

SJ 172550 is a MDMX inhibitor (EC50 = 2.3 μM), controls the biological activity of MDMX.

(CAS: 1309684-94-3)

RO8994, a spiroindolinone derivative, is an effective MDM2 inhibitor and has been found to have prabable activity against haematological malignancies. IC50: 5 n...

CAS 1005264-47-0 MX69

(CAS: 1005264-47-0)

MX69 inhibits expression of both MDM2 and XIAP, used for cancer treatment. MX69 blocks the MDM2 protein-XIAP RNA interaction, leading to MDM2 degradation.

CAS 511296-88-1 Pifithrin-β hydrobromide

Pifithrin-β hydrobromide
(CAS: 511296-88-1)

Pifithrin-β hydrobromide is a reversible inhibitor of p53-dependent transcription and apoptosis, inhibits the growth of the cancer cell lines IGROV-1 (IC50 = 23...

CAS 675576-97-3 Nutlin-3b

(CAS: 675576-97-3)

Nutlin-3b, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM.

Chemical Structure

CAS 1229705-06-9 Idasanutlin

Quick Inquiry

Verification code

Featured Items